Founded in 2007
Chemclin Diagnostics Co., Ltd (hereinafter it was referred to as Chemclin Diagnostics), founded in 2007, is one of the pioneers in developing clinical immunoassays and systems in China. Chemclin Diagnostics is specialized in the research and development, production, sales and service of In Vitro Diagnostics (IVD) products.
Beyond Biotech (Shanghai) Co., Ltd located in Shanghai Pilot Free Trade Zone, is a wholly-owned subsidiary of Chemclin Diagnostics.
- 10 more yearsSelection, Training and Integration
- 60 %Overseas Study and Multinational Working Experiences
- 10 years10 More Years Serving at Chemclin Diagnostics
Vision and ambition lead the development and the future of Chemclin Diagnostics. The development of an enterprise is inseparable from strong leadership and management team. Under the leadership of Mr. Li, Lin, a former senior executive of a multinational company with more than 20 years of management experience in IVD industry, Chemclin Diagnostics has successfully built up a high-level management team with global backgrounds and professional experiences. Meanwhile, after more than 10 years of selection, training and integration, the management team has accumulated comprehensive industry knowledge and practical experience. In particular, Chemclin Diagnostics has very rare successful experience in the domestic IVD industry in terms of technology upgrading and company acquisition, integration and transformation.
About 60% of the management members of Chemclin Diagnostics have the overseas study or working experiences in multinational companies. Meanwhile, approximately 60% of the management team members have been serving in Chemclin for more than 10 years. Chemclin Diagnostics also attaches great importance to the selection and training of key talents in the middle level, especially the managers. After years of efforts, Chemclin Diagnostics has built up a middle management team with professionalism, enthusiasm, solidarity and mutual assistance, which has laid a solid foundation for the company’s long-term development.
Multiple Panels and Varieties of Immunoassays
Series of Automated SystemsCurrently, chemiluminescence immunology is the core business of Chemclin Diagnostics. In terms of technology, from the product development of radioimmunoassay and enzymatic chemiluminescence immunoassay to the cross-generation technology platform of Light-initiated Chemiluminescence Immunoassay (LiCA), Chemclin’s R&D team has accumulated rich experiences in the product development on assays and automated systems. Among them, LiCA is a leading immunoassay technology platform in both China and overseas. LiCA is a unique technology with the integration of varies of cutting edge technologies, such as nanoparticle polymers, light-initiated chemiluminescent signaling technology, wash-free immunoassay technology and the corresponding automation technologies. LiCA is developed by a technical team led by Professor Zhao Wei Guo, a senior overseas scholar and Chief Technology Officer (CTO), with years of efforts. At present, Chemclin Diagnostics has successfully developed assays for multiple disease panels and series of automated LiCA systems.
Core Value
Serving Human Health with Technologies
Operation Principles
Customer Focused Quality Valued Innovation Driven Result Oriented
In the 21st century, China and other developing countries around the world are facing with numerous developing opportunities, but also with many difficulties and challenges. While enjoying the many benefits of technological progress and economic development, people, as well as the society are also facing the challenges of environmental deterioration, population aging and various diseases. In particular, the government shall provide affordable health care for its people, which requires the medical device and pharmaceutical industry to develop the products with excellent performance and cost competitiveness. Chemclin Diagnostics will keep on innovation on technology as well as management and will continuously stick to the company’s core value and operation principles, in order to develop the innovative and cost-effective diagnostic products and make its due contributions to the health of people in China and other developing countries. In this process, Chemclin Diagnostics will continuously create customer value, employee value as well as the shareholder value.
